Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing ERCP
Status:
Not yet recruiting
Trial end date:
2021-05-25
Target enrollment:
Participant gender:
Summary
This study is designed to compare the effects of a single dose Ondansetron 4mg versus
Palonosetron 75mcg in the prophylaxis against early & delayed postoperative nausea and
vomiting in the first 48 hours post-operatively in patients undergoing Endoscopic Retrograde
Cholangio-Pancreatography (ERCP) to determine the complete response, complete control and
failure rates.